#USA #Montreal #CellCarta #SonicHealthcare #CompanionDiagnostics

Strategic Partnership Between CellCarta and Sonic Healthcare

CellCarta, recognized as a leading global Contract Research Organization (CRO) laboratory catering to the biopharmaceutical sector, has recently announced a strategic partnership with Sonic Healthcare USA, Inc. This partnership is pivotal as it establishes Sonic as the first committed commercial laboratory partner within CellCarta's innovative Lab Network strategy, aimed at enhancing the commercialization of companion diagnostics (CDx) developed via a single-site Pre-Market Approval (PMA) bridging model.

The emergence of this strategic partnership marks a significant milestone in the evolution of biopharmaceutical research. With the increasing complexity of precision medicine, especially in fields such as oncology and autoimmune diseases, there is a pressing need for an efficient commercialization strategy for CDx. The partnership is set to address these specific needs by devising a systematic approach to facilitate the transition from diagnostics development and regulatory approval to actual market deployment.

CellCarta's unique model allows them to develop companion diagnostics, compile necessary analytical and clinical evidence, and navigate the regulatory pathways required by the U.S. FDA and European IVDR. Meanwhile, Sonic Healthcare will serve as the critical interface connecting providers and patients, ensuring that the transition from laboratory approval to clinical application is seamless. This collaboration not only provides an efficient pathway for order flow and enhances customer relationships but also aims at achieving effective market access across geographical targets.

Dusty Tenney, the CEO of CellCarta, emphasized the necessity of this partnership stating, "Biopharma companies increasingly want a faster, more controlled path to companion diagnostic approval, but they also need a credible route to commercialization once that approval is secured."

This partnership is especially noteworthy for its commitment to promoting rapid assay deployment, meeting rigorous regulatory standards, and ensuring effective commercial execution. By serving as the first laboratory partner within the CellCarta Lab Network, Sonic Healthcare's involvement ensures high-quality services are available to clinicians and patients, providing necessary support in a timely manner.

Ehab A. El-Gabry, MD, Chief Medical Officer at CellCarta, added further insights regarding this model, "Too often, single-site CDx strategies are perceived as limiting patient reach. This model is different. We support sponsors end-to-end—from assay development through regulatory submission and enable commercialization through laboratory partners with established provider networks."

By integrating CellCarta’s development and testing capabilities with Sonic Healthcare's laboratory network, the partnership focuses on helping biopharma sponsors facilitate quicker access to approved companion diagnostics without losing the integrity of assay continuity and quality.

As the demand for precision medicine continues to rise, CellCarta is optimistic about its Lab Network strategy's future expansion. This initiative is not only expected to create a robust platform for the commercialization of companion diagnostics but is also positioned to accommodate future geographic expansion and adapt to various bridging strategies. As the model garners attention in the market, discussions with additional laboratory partners are ongoing, aiming to develop a global network that enhances access to these critical diagnostics.

Sonic Healthcare USA continues to strive towards making high-quality diagnostic testing widely available, thereby informing clinical decisions effectively. The partnership with CellCarta signifies a shift towards a more integrated healthcare service that enhances patient care through innovation and collaboration in the diagnostics field.

This strategic alliance heralds a new phase in how companion diagnostics are approached and delivered, providing vital support as biopharmaceutical companies navigate the intricate waters of regulatory approval and commercial success. By combining their strengths, CellCarta and Sonic Healthcare are poised to lead the way in precision medicine, ultimately benefiting healthcare professionals and patients alike.